文献速递糖尿病

妊娠糖尿病女性连续血糖监测指标与妊娠结局:DiGest试验二次分析

Continuous Glucose Monitoring Metrics and Pregnancy Outcomes in Women With Gestational Diabetes Mellitus: A Secondary Analysis of the DiGest Trial.
PubMed 文献 · Diabetes Care · 2025-08-19

本研究为DiGest试验的二次分析,纳入425例妊娠糖尿病(GDM)女性,在孕29、32、36周佩戴盲法Dexcom G6连续血糖监测(CGM)。分析显示孕29周CGM指标与大于胎龄儿(LGA)和小于胎龄儿(SGA)显著相关;达到平均血糖<110 mg/dL、妊娠特异性目标范围内时间(TIRp)≥90%或高于范围时间(TARp)<10%者,LGA和SGA风险显著降低。

要点

  • 孕29周CGM指标与LGA和SGA风险显著相关。
  • 平均血糖<110 mg/dL、TIRp≥90%或TARp<10%与LGA和SGA风险降低相关。
  • TARp<10%和夜间平均血糖<110 mg/dL与早产风险降低相关。

核心结论

  • 在GDM女性中,孕29周时平均血糖<110 mg/dL(6.1 mmol/L)、TIRp≥90%或TARp<10%(范围63-140 mg/dL)与子代不良结局低风险相关。

研究设计与样本

  • DiGest试验的二次分析,纳入425例GDM女性(中位诊断孕周25.1周,BMI≥25 kg/m²),接受饮食干预,并在孕29、32、36周进行盲法Dexcom G6 CGM监测。

主要发现

  • 孕29周CGM指标与LGA和SGA显著相关。
  • 达到平均血糖<110 mg/dL、TIRp≥90%或TARp<10%者,LGA风险显著降低(OR分别为0.41、0.38、0.39)。
  • 达到上述指标者SGA风险也显著降低(OR分别为0.26、0.30、0.19)。
  • TARp<10%和夜间平均血糖<110 mg/dL与早产风险降低相关(OR分别为0.40和0.42)。
  • 更严格范围(63-120 mg/dL)总体表现相似,但无单一稳健的TIR/TAR目标适用于所有结局。

关键数值与推荐

  • 平均血糖<110 mg/dL(6.1 mmol/L)对应LGA的OR 0.41(95%CI 0.22-0.77),SGA的OR 0.26(95%CI 0.08-0.79)。
  • TIRp≥90%对应LGA的OR 0.38(95%CI 0.20-0.70),SGA的OR 0.30(95%CI 0.10-0.91)。
  • TARp<10%对应LGA的OR 0.39(95%CI 0.20-0.73),SGA的OR 0.19(95%CI 0.06-0.62),早产的OR 0.40(95%CI 0.17-0.94)。
  • 夜间平均血糖<110 mg/dL对应早产的OR 0.42(95%CI 0.19-0.97)。

临床怎么用

  • 对于GDM女性,孕29周CGM指标(平均血糖、TIRp、TARp)可用于识别子代不良结局高风险者。
  • 达到平均血糖<110 mg/dL、TIRp≥90%或TARp<10%可能作为临床管理目标,但需个体化。

局限性

  • 本研究为二次分析,结果需进一步验证。
  • 更严格范围(63-120 mg/dL)无单一稳健目标,提示目标设定需综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Continuous glucose monitoring (CGM) is increasingly used in gestational diabetes mellitus (GDM), but optimal metrics, ranges, and targets in this population are undefined. We assessed associations between CGM metrics and pregnancy outcomes in GDM. RESEARCH DESIGN AND METHODS: During the DiGest study, 425 women with GDM (diagnosed at median [IQR] 25.1 [18.3-27.7] weeks) and BMI ≥25 kg/m2 received a dietary intervention, with masked Dexcom G6 CGM at 29 (n = 361), 32 (n = 215), and 36 (n = 227) weeks' gestation. For this secondary analysis, we used logistic regression, receiver operating characteristic curves, and the Youden index to assess associations and predictive ability of CGM metrics, including pregnancy-specific time in range (TIRp) (63-140 mg/dL [3.5-7.8 mmol/L]) and pregnancy outcomes. RESULTS: CGM metrics at 29 weeks were significantly associated with large for gestational age (LGA) and small for gestational age (SGA). Participants achieving mean glucose <110 mg/dL (6.1 mmol/L), TIRp ≥90%, or pregnancy-specific time above range (TARp) <10% at 29 weeks had a significantly lower risk of LGA (odds ratio [OR] 0.41 [95% CI 0.22, 0.77], 0.38 [0.20, 0.70], and 0.39 [0.20, 0.73], respectively) and SGA (0.26 [0.08, 0.79], 0.30 [0.10, 0.91], and 0.19 [0.06, 0.62], respectively). TARp <10% and mean nocturnal glucose <110 mg/dL (6.1 mmol/L) were associated with a reduced odds of preterm birth (OR 0.40 [0.17, 0.94] and 0.42 [0.19, 0.97], respectively). A stricter range (63-120 mg/dL [3.5-6.7 mmol/L]) had similar performance overall, but had no single statistically robust TIR/TAR target across all outcomes. CONCLUSIONS: In women with GDM, CGM mean glucose <110 mg/dL (6.1 mmol/L), ≥90% TIRp, or <10% TARp using a range of 63-140 mg/dL (3.5-7.8 mmol/L) at 29 weeks' gestation was associated with a low risk of suboptimal offspring outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kusinski LC, Atta N, Jones DL, et al. Continuous Glucose Monitoring Metrics and Pregnancy Outcomes in Women With Gestational Diabetes Mellitus: A Secondary Analysis of the DiGest Trial. Diabetes Care. 2025. PMID: 40828742. doi:10.2337/dc25-0452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。